ArticleInternational journal of nanomedicine2017
Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control.Materials today. Bio · 2026Article
- Surface functionalized nanomaterial systems for targeted therapy of endocrine related tumors: a review of recent advancements.Drug delivery · 2024Review
- Regulating Cholesterol in Tumorigenesis: A Novel Paradigm for Tumor Nanotherapeutics.International journal of nanomedicine · 2024Review
- Nanotechnologies meeting natural sources: Engineered lipoproteins for precise brain disease theranostics.Asian journal of pharmaceutical sciences · 2023Review
- Phase-Separated Liposomes Hijack Endogenous Lipoprotein Transport and Metabolism Pathways to Target Subsets of Endothelial Cells In Vivo.Advanced healthcare materials · 2023Article
- Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.Journal of nanobiotechnology · 2023Article
- Apolipoprotein mimetics in cancer.Seminars in cancer biology · 2021Review
- Head-to-Head Comparison of the Penetration Efficiency of Lipid-Based Nanoparticles into Tumor Spheroids.ACS omega · 2020Article
- Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents.Nanomaterials (Basel, Switzerland) · 2020Review
- Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence.The Journal of pharmacology and experimental therapeutics · 2020Article
- Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma.International journal of molecular sciences · 2020Article
- Lipoprotein-based drug delivery.Advanced drug delivery reviews · 2020Review
- Article
- Nanoparticle systems for cancer vaccine.Nanomedicine (London, England) · 2019Review
- High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.ACS nano · 2019Article
- Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Advances in adrenal tumors 2018.Endocrine-related cancer · 2018Review
- Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.Surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and has a 5-year survival rate of <35%. ACC cells require cholesterol for steroid hormone production, and this requirement is met via expression on the cell surface of a high level of SRB1, responsible for the uptake of high-density lipoproteins (HDLs), which carry and transport cholesterol in vivo. Here, we describe how this natural lipid carrier function of SRB1 can be utilized to improve the tumor-targeted delivery of a novel natural product derivative - withalongolide A 4,19,27-triacetate (WGA-TA) - which has shown potent antitumor efficacy, but poor aqueous solubility. Our strategy was to use synthetic HDL (sHDL) nanodisks, which are effective in tumor-targeted delivery due to their smallness, long circulation half-life, documented safety, and ability to bind to SRB1. In this study, we prepared sHDL nanodisks using an optimized phospholipid composition combined with ApoA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.